You are here: Industry Insights > CureVac

News List

CureVac and Bayer Join Forces contractpharma
January 08, 2021
Bayer has signed a collaboration and services agreement with CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA).
CureVac initiates Phase IIb/III trial of Covid-19 vaccine candidate pharmaceutical-technology
December 16, 2020
German company CureVac has enrolled the first participant in the pivotal Phase IIb/III HERALD study to evaluate the safety and efficacy of its mRNA vaccine candidate, CVnCoV, against Covid-19.
CureVac and Wacker Sign Contract for Manufacturing of Covid-19 Vaccine Candidate contractpharma
November 25, 2020
Manufacturing at Wacker’s biotech site in Amsterdam is scheduled to start in the first half of 2021.
EU signs COVID-19 vaccine deal with CureVac pharmatimes
November 19, 2020
The European Commission has signed a contract with CureVac for access to 405 million doses of its investigational COVID-19 vaccine.
CureVac to Ramp Up Mfg. of COVID-19 Vax Candidate CVnCoV contractpharma
November 18, 2020
Will partner with CDMOs to increase manufacturing capacities for CVnCoV to up to 300 million doses in 2021 and up to 600 million doses in 2022.
Germany awards €750m to BioNTech and CureVac for Covid-19 vaccines pharmaceutical-technology
September 17, 2020
The German Government has granted a total of up to €750m in funding to domestic firms BioNTech and CureVac to support the work on their respective Covid-19 vaccine candidates.
CureVac to Receive €252M to Support COVID-19 Vax Development contractpharma
September 07, 2020
The German Federal Ministry of Education and Research grant is also expected to be used for the rapid expansion of vaccine production.
CureVac expects to produce COVID-19 vaccine at scale by year-end expresspharma
September 07, 2020
It is one of a number of firms developing vaccines based on molecules carrying a genetic code called messenger RNA (mRNA) to treat diseases.
CureVac concludes talks with EC for Covid-19 vaccine supply pharmaceutical-technology
August 24, 2020
German biopharmaceutical firm CureVac has concluded exploratory discussions with the European Commission (EC) on an advanced purchase agreement (APA) for the company’s mRNA-based Covid-19 vaccine candidate.
CureVac and EU Discuss Advanced Purchase Agreement contractpharma
August 21, 2020
CureVac, a clinical-stage biopharmaceutical company, and the European Commission have concluded exploratory talks outlining an Advanced Purchase Agreement (APA) for CureVac’s potential mRNA-based COVID-19 vaccine.

Previous page 1 2 3 4 5 Next page